Die Behandlung von Risikofaktoren zur Primärprophylaxe zerebraler Ischämien

Zerebrovaskuläre Erkrankungen gehören weltweit zu den häufigsten Todesursachen. In Deutschland erkranken etwa 150 000 Einwohner pro Jahr neu an einem Schlaganfall. Zerebrale Ischämien sind die häufigste Ursache frühzeitiger Invalidität. Sie verursachen großes individuelles Leid, die Folgekosten erreichen volkswirtschaftlich relevante Summen [41]. Schlaganfälle können verhindert werden; die hohe Prävalenz und das Wissen um Risikofaktoren prädestinieren diese Erkrankung für präventive Maßnahmen [18]. In dieser Übersichtsarbeit sollen Risikofaktoren für die Entstehung zerebraler Ischämien und ihre Behandlungsmöglichkeiten erörtert werden. Bezüglich der Risikofaktoren für hämorrhagische Infarkte sei auf andere Arbeiten verwiesen [34].

Literatur

• 1 Alfthan G, Pekkanen J, Jauhiainen M. et al . Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.  Atherosclerosis. 1994;  106 9-19
• 2 Allenberg J, Brandt T, Thron A. Percutane transluminale Angioplastie und Stenting bei Stenosen der A. carotis interna.  Nervenarzt. 1999;  70 314
• 3 American Diabetes Association . Clinical practice recommendations.  Diabetes Care. 1998;  21 1-89 (suppl.1))
• 4 Anderson J L, Muhlestein J B, Carlquist J. et al . Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection.  Circulation. 1999;  99 1540-1547
• 5 Antiplatelet Trialists Collaboration . Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
• 6 Biller J, Feinberg W, Castaldo J. et al . Guidelines for carotid endarterectomy: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.  Circulation. 1998;  97 501-509
• 7 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes.  JAMA. 1995;  274 1049-1057
• 8 Collins R, Peto R, MacMahon S. et al . Blood pressure, stroke, and coronary heart disease. Part 2, Short term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context.  Lancet. 1990;  335 827-838
• 9 Cromwell J, Bartosch W J, Fiore M C, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy Research.  JAMA. 1997;  278 1759-1766
• 10 Dyken M E, Somers V K, Yamada T, Ren Z Y, Zimmerman M B. Investigating the relationship between stroke and obstructive sleep apnea.  Stroke. 1996;  27 401-407
• 11 European Atrial Fibrillation Trial Study Group . Optimal oral anticoagulattion therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia.  N Engl J Med. 1995;  333 5-10
• 12 Executive Committee for the Asymptomatic Carotid Atherosclerosis Study . Endarterectomy for asymptomatic carotid artery stenosis.  JAMA. 1995;  273 1421-1428
• 13 Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease.  Stroke. 1999;  30 299-305
• 14 Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy.  Lancet. 1999;  353 1586-1587
• 15 Flemming M F, Barry K L, Manwell L B, Johnson K, London R. Brief physician advice for problem drinkers.   JAMA. 1997;  277 1039-1045
• 16 Gillman M W, Cupples L A. et al . Protective effect of fruits and vegetables on development of stroke in men.  JAMA. 1995;  273 1113-1117
• 17 Gupta S, Leatham E W, Carrington D, Mendall M A, Kaski J C, Camm A J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.  Circulation. 1997;  96 404-407
• 18 Gorelick P B, Sacco R L, Smith D B. et al . Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association.  JAMA. 1999;  281 1112-1120
• 19 Gorelick P B, Schneck M, Berglund L F, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke.  Neuroepidemiology. 1997;  16 107-115
• 20 Grau A J, Buggle F, Ziegler C. et al . Association between acute cerebrovascular ischemia and chronic and recurrent infection.  Stroke. 1997;  28 1724-1729
• 21 Hankey G J, Warlow C P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.  Lancet. 1999;  354 1457-1463
• 22 Jorenby D E, Leischow S J, Nides M A. et al . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.  N Engl J Med. 1999;  340 685-691
• 23 Kawachi I, Colditz G A, Stampfer M J. et al . Smoking cessation and decreased risk of stroke in women.  JAMA. 1993;  269 232-236
• 24 Kiely D K, Wolf P A, Cupples L A. et al . Physical activity and stroke risk: The Framingham Study.  Am J Epidemiology. 1994;  140 608-620
• 25 Kronmal R A, Hart R G, Manolio T A, Talbert R L, Beauchamp N J, Newman A. Aspirin use and incident stroke in the Cardiovascular Health Study.  Stroke. 1998;  29 887-894
• 26 Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation.  Chest. 1995;  108 352-359 (suppl 4))
• 27 Lee I M, Paffenbarger R S. Physical activity and stroke incidence. The Harvard Alumni Health Study.  Stroke. 1998;  29 2049-2054
• 28 Matchar D B, McCrory D C, Bamen H J, Feussner J R. Medical treatment for stroke prevention.  Annals Int Med. 1994;  121 41-53
• 29 Mathias K, Jäger H, Sahl H, Hennigs S, Gißler H M. Die Endoluminale Therapie der Karotisstenose.  Deutsches Ärzteblatt. 1999;  96 2502-2508
• 30 Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacous as first-line therapy for hypertension in the elderly? A systematic review.  JAMA. 1998;  279 1903-1907
• 31 Perry I, Refsum H, Morris R, Ebrahim S, Ueland P, Shaper A. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet. 1995;  346 1395-1398
• 32 Prystowsky E N, Benson D W Jr, Fuster V. et al . Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Aosociafion.  Circulation. 1996;  93 1262-1277
• 33 Report of the Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation.  Neurology. 1998;  51 671-673
• 34 Sacco R L, Benjamin E J, Broderick J P. et al . Risk factors.  Panel Stroke. 1997;  28 1507-1517
• 35 Sacks F M, Pfeffer M A, Moye L A. et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recunent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
• 36 Saikku P, Leinonen M, Mattila K J. et al . Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease an acute myocardial infarction.  Lancet. 1988;  2 (8618) 983-986
• 37 Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study.  Lancet. 1994;  344 1383-1389
• 38 SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.   JAMA. 1991;  265 3255-3264
• 39 Sievert H, Pfeil W, Bösenberg I, Spies H, Theis R, Beykirch K F. Primäre Stent-Implantation in der Arteria carotis interna.  Dtsch med Wschr. 1999;  124 1262-1266
• 40 Steering Committee of the Physicians Health Study Research Group . Final report on the aspirin component of the ongoing Physicians Health Study.  N Engl J Med. 1989;  321 129-135
• 41 Taylor T N, Davis P H, Tomer J C, Holmes J, Meyer J W, Jacobson M F. Lifetime cost of stroke in the United States.  Stroke. 1996;  27 1459-1466
• 42 The Atrial Fibrillation Investigators . The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from 3 randomized trials.  Arch Intern Med. 1997;  157 1237-1240
• 43 The Diabetes Control and Complications Trial Group . Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.  Am J Cardiol. 1995;  75 894-903
• 44 The Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure . The 6th report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.  Arch Intern Med. 1997;  157 2413-2446
• 45 The National Cholesterol Education Program (NCEP) Expert Panel . Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel in Adults (Adult Treatment Panel II).  JAMA. 1993;  269 3015-3023
• 46 UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33.  Lancet. 1998;  352 837-853
• 47 UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascuiar and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;  317 703-713
• 48 Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.  Stroke. 1994;  25 1924-1930
• 49 Wolf P A, Abbott R D, Kannel W B. Atrial Fibrillation as an independent risk factor for stroke: The Framingham Study.  Stroke. 1991;  22 983-988
• 50 Wolf P A, DAgostino R B, Kannel W B, Bonita R  Belanger AJ. Cigarette smoking as a risk factor for stroke: The Framingliam Study.  JAMA. 1998;  259 1025-1029

Korrespondenz